BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3603-3607

  Gatto, Carmen ^a   Rieppi, Monica ^a   Borsotti, Patrizia ^a   Innocenti, Silvia ^a   Ceruti, Roberta ^a,b   Drudis, Teresa ^c   Scanziani, Eugenio ^b   Casazza, Anna M ^d   Taraboletti, Giulia ^a   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4,4 (CHLOROPHENYL)PHENYL] 4 OXO (PHENYLTHIOMETHYL)BUTANOIC ACID; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELLS, CULTURED; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; LAMININ; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; ORGANIC CHEMICALS; PROTEOGLYCANS; UMBILICAL VEINS;

EID: 0032710567     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
2. Ingber, D. E., and Folkman, J. How does extracellular matrix control capillary morphogenesis? Cell, 58: 803-805, 1989.
3. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
4. Kleiner, D. E., and Stetler-Stevenson, W. G. Structural biochemistry and activation of matrix metalloproteases. Curr. Opin. Cell Biol., 5: 891-897, 1993.
5. DeClerck, Y. A., Imren, S., Montgomery, A. M. P., Mueller, B. M., Reisfeld, R. A., and Laug, W. E. Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol., 425: 89-97, 1997.
6. Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell, 91: 439-442, 1997.
7. Schnaper, H. W., Grant, D. S., Stetler-Stevenson, W. G., Fridman, R., D'Orazi, G., Murphy, A. N., Bird, R. E., Hoythya, M., Fuerst, T. R., French, D. L., Quigley, J. P., and Kleinman, H. K. Type IV collagenase(s) and TIMPS modulate endothelial cell morphogenesis in vitro. J. Cell. Physiol., 156: 235-246, 1993.
8. Nielson Schnack, B., Sehested, M., Kjeldson, L., Borregaard, N., Rygaard, J., and Dano, K. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer. Lab. Investig., 77: 345-355, 1997.
9. Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., and Werb, Z. MMP-9/ gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93: 411-422, 1998.
10. Lewalle, J. M., Munaut, C., Pichot, B., Cataldo, D., Baramova, E., and Foidart, J. M. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells. J. Cell. Physiol., 165: 475-483, 1995.
11. Brown, P. D., and Giavazzi, R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann. Oncol., 6: 967-974, 1995.
12. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
13. MacDougall, J. R., and Matrisian, L. M. Contributions of tumor and stroma matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev., 14: 351-362, 1995.
14. Wojtowicz-Praga, S. M., Dickson, R. B., and Hawkins, M. J. Matrix metalloproteinase inhibitors. Invest. New Drugs, 15: 61-75, 1997.
15. Flynn, C., Bull, C., Eberwein, D., Matherne, C., and Hibner, B. Anti-metastatic activity of BAY 12-9566 in human colon carcinoma HCT116 orthotopic model. Proc. Am. Assoc. Cancer Res., 39: 30, 1998.
16. Hibner, B., Bull, C., Flynn, C., Eberwein, D., Garrison, T., Casazza, A., Carter, C., and Gibson, N. Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous and metastatic in vivo models. Ann. Oncol., 9 (Suppl. 2): 75, 1998.
17. Hirte, H., Goel, R., Bennet, K., Elias, I., Shah, A., and Seymour, L. Phase I study of the matrix metalloprotease inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer. Ann. Oncol., 9 (Suppl. 2): 75, 1998.
18. Nozaki, S., Sissons, S., Casazza, A. M., and Sledge, G. W. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice. Proc. Am. Assoc. Cancer Res., 39: 301, 1998.
19. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsotti, P., Scanziani, E., Brown, P. D., and Giavazzi, R. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst., 87: 293-298, 1995.
20. Belotti, D., Vergani, V., Drudis, T., Borsotti, P., Pitelli, M. R., Viale, G., Giavazzi, R., and Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res., 2: 1843-1849, 1996.
21. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., and Martin, G. R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig., 67: 519-528, 1992.
22. Hiraoka, N., Allen, E., Apel, I. J., Gyetko, M. R., and Weiss, S. J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell, 95: 365-377, 1998.
23. Brubaker, W. F., Perrino, P., Wu, Y., Jaworski, S., Town, C., Jones, L., Ward, D., and Chien, D. S. Pharmacokinetics of BAY 12-9566 in animals: species comparison. Proc. Am. Assoc. Cancer Res., 40: 391, 1999.
24. Goel, R., Hirte, H., Major, P., Waterfield, B., Holohan, S., Bennett, K., Elias, I., and Seymour, L. Clinical pharmacology of the metalloproteinase (MMP) and angiogenesis inhibitor Bayer 12-9566 in cancer patients. Proc. Am. Soc. Clin. Oncol., 18: 160a, 1999.